ClinicalTrials.gg
RecruitingNCT07021456DIABEAUpdated Jun 15, 2025

Impact of Dietary Knowledge Related to Functional Insulin Therapy in Type 1 Diabetes on the Risk of Eating Disorders

An observational study in Type 1 Diabetes (T1D), sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by University Hospital, Grenoble · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · University Hospital, Grenoble.

Started
2025
with 1 other
Observational
7 of 18
2 open now
Registered
17th of 18
by date

Among the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 17th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble, or all of them as a file.
02

Study summary

Background: The management of type 1 diabetes (T1D) relies on exogenous insulin administration to compensate for the lack of endogenous insulin production. Optimal glycemic control, essential for preventing long-term complications, requires precise insulin dose adjustments based on carbohydrate intake. Functional insulin therapy (FIT) allows for flexibility in insulin dosing according to carbohydrate consumption, thereby reducing the dietary constraints previously imposed on patients. However, this approach requires increased attention to dietary intake. Individuals with T1D already have a heightened risk of developing eating disorders (EDs). We hypothesize that the dietary knowledge required for FIT may contribute to rigid eating behaviors, thereby increasing the risk of EDs.

Objective: This prospective monocentric study aims to determine whether dietary knowledge related to FIT is associated with an increased risk of EDs in individuals with T1D.

Methods: The primary outcome measure is the correlation between the Gluciquizz score (a validated tool assessing FIT knowledge) and the risk of EDs, evaluated using the DEPS-R questionnaire (a validated screening tool for ED risk in T1D patients). In addition to this quantitative analysis, a qualitative study will be conducted through semi-structured interviews to explore in greater depth the patients' experiences, their relationship with food, and their perceptions of FIT-related requirements.

Perspectives: This study aims to improve the understanding of the impact of FIT on ED risk in T1D. The findings may help identify at-risk patient profiles and enhance therapeutic education and patient management by integrating ED risk considerations. The qualitative approach will provide further insight into patients' individual experiences, facilitating recommendations tailored to their specific needs.

Read the detailed description

STUDY DESCRIPTION

This is a Type 3 study under the Jardé law, involving human subjects:

Observational study Prospective design Monocentric National scope

We selected this study design to minimize participant burden (data collection conducted online, by phone, or via videoconference, eliminating the need for patient travel). Recruitment through patient association websites and social media will enable a national reach.

The study will take place in four phases:

Recruitment Videoconference for a questionnaire on FIT-related dietary knowledge and ED risk assessment Self-administered online questionnaire Videoconference interview

SELECTION AND INCLUSION VISIT

If the participant wishes to join the study, they can either scan the QR code or visit the web link provided in the recruitment announcement. This QR code or link will redirect to a page detailing the study, the eligibility criteria that the participant must complete, and the information notice. The participant will enter their email address in the designated field and will also have the option to download the information notice if they wish.

Once this step is completed, the principal investigator will verify the eligibility criteria. If the participant meets the criteria, they will receive an email containing the necessary information for the next steps of the study:

Non-opposition letter - Part 1 A personal identifier number (formatted as initials + number, e.g., LA01) to pseudonymize questionnaire and self-reported responses A calendar allowing them to indicate their preferred date for the videoconference A link to access the videoconference

To ensure that the participant fully understands the study procedures, the clinical research associate (CRA) will go over the project details during the first videoconference and address any questions. The CRA will also check that the non-opposition form has been properly completed before integrating it into the study records.

If the participant does not meet the eligibility criteria, they will receive an email notifying them of their ineligibility.

The principal investigator will maintain a correspondence table containing the participant's name, surname, email address, and personal identifier number.

Participants will be fully and transparently informed in clear and understandable terms about the study objectives, the nature of the collected data, and their right to withdraw their consent at any time. The investigator must also inform participants about the opinion issued by the Ethics Committee (Comité de Protection des Personnes - CPP).

Participants can exercise their right to oppose the processing of their health data for research purposes at any time by contacting either the research coordinator or the institution responsible for the data. The institution is committed to responding to such requests within a maximum of two months.

FOLLOW-UP VISITS

The study will be conducted in three distinct phases:

  1. First Phase: Videoconference for Questionnaire Completion

    A clinical research associate (CRA) will contact the participant to administer the questionnaires. The CRA will directly enter the participant's responses into the Redcap online platform.

    At the end of this interview, the investigator will invite participants to take part in the qualitative phase of the study (third phase: semi-structured videoconference interview). Participants will be progressively included until data saturation is reached.

    If the participant agrees, the investigator will send a second email with a second non-opposition form - Part 2 (Appendix 4) for participation in the qualitative interview.

    For all participants, a Redcap platform link will be emailed to them to complete the self-reported questionnaires.

  2. Second Phase: Online Self-Questionnaires

    Participants will receive a link to complete self-administered questionnaires directly on Redcap. Contact information for the CRA or investigator will be provided in case of technical issues.

  3. Third Phase: Semi-Structured Videoconference Interview

This interview will be semi-structured and will follow the interview guide provided in Appendix 12. Participants will be included in this phase until data saturation is reached.

For the first and third phases, we have chosen to conduct interviews via the BigBlueButton videoconferencing platform, which is GDPR-compliant. We aim to use a platform that is user-friendly and free for participants.

Since BigBlueButton is integrated with the Université Grenoble Alpes information system, no additional identification data will be processed. The following personal data-voice and image-will be recorded by the interview organizer.

If the recording feature is activated, participants will be explicitly notified via a specific message. The recordings will be used exclusively for the transcription of data.

03

Conditions studied

  • Type 1 Diabetes (T1D)

Keywords

  • eating disorders
  • functional insulin therapy
  • type 1 diabetes
  • dietary knowledge
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

We aim to include patients with type 1 diabetes (T1D) in France. Participants will be enrolled in the study regardless of their current treatment.

We will reach out to French patient associations for individuals with T1D, such as the Fédération Française des Diabétiques, to request the dissemination of our recruitment announcement to their members. The announcement will also be published on social media. Recruitment will be based on an online announcement, attached in Appendix 1.

Additionally, we will propose to the Endocrinology Department at CHU Grenoble-Alpes to display the recruitment announcement in their waiting rooms to present it to their patients. If these recruitment channels do not yield a sufficient number of participants, we will expand dissemination to other hospital departments at the national level.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 1 diabetes confirmed by a referring physician
  • Diagnosis received at least three months prior
  • Adult (18 years or older)
  • Access to a computer or smartphone capable of videoconferencing
  • No expressed opposition to participation
  • Consent for image rights (for Phase 2 qualitative interviews)

Exclusion criteria

Exclusion Criteria:

  • Inability to complete online questionnaires and participate in a 45-minute videoconference interview
  • Being under legal guardianship or curatorship
  • Being pregnant or breastfeeding
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. to determine whether dietary knowledge related to functional insulin therapy (FIT) is associated with the risk of developing eating disorders (EDs)

    the correlation between the Gluciquizz score (a validated tool assessing FIT knowledge) and the risk of EDs, as measured by the DEPS-R questionnaire.

    Time frame: Day 1

Secondary outcomes

  1. To determine whether dietary knowledge related to FIT is associated with the risk of EDs according to the SCOFF-F questionnaire (a validated French screening tool for EDs).

    Correlation between the Gluciquizz score (validated for assessing FIT knowledge) and the risk of EDs according to the SCOFF-F questionnaire.

    Time frame: Day 1

  2. To assess whether the following factors influence the risk of developing EDs: a. Quality of life

    Comparison of the following factors: quality of life (measured by ADDQoL, unit: individual weighted impact score) between two groups defined by the DEPS-R threshold (≤ 20 vs. \> 20, indicating ED risk).

    Time frame: Day 1

  3. To identify whether specific patient profiles at risk of developing EDs emerge based on the collected variables.

    Identification of patient profiles based on the following variables: FIT knowledge (Gluciquizz, unit: percentage of correct responses), quality of life (ADDQoL, unit: individual weighted impact score), diabetes-related anxiety (PAID, unit: total score ranging from 0 to 100), fear of hypoglycemia (HFS-II, unit: total score ranging from 0 to 33 for the behavior subscale and 0 to 45 for the worry subscale), diabetes duration (unit: years), and treatment (unit: type of treatment, e.g., insulin therapy, oral antidiabetic drugs), with DEPS-R (unit: total score ranging from 0 to 30) as an illustrative variable.

    Time frame: Day 1

  4. To explore the influence of functional insulin therapy on eating behaviors through semi-structured interviews.

    Insights into the decision-making factors influencing food choices among individuals with type 1 diabetes, following qualitative study methodologies.

    Time frame: Day 1

  5. To assess whether the following factors influence the risk of developing EDs: b. Diabetes-related anxiety

    Comparison of the following factors: diabetes-related anxiety (PAID, unit: total score ranging from 0 to 100) between two groups defined by the DEPS-R threshold (≤ 20 vs. \> 20, indicating ED risk).

    Time frame: Day 1

  6. To assess whether the following factors influence the risk of developing EDs: c. fear of hypoglycemia

    Comparison of the following factors: fear of hypoglycemia (HFS, unit: total score ranging from 0 to 8) between two groups defined by the DEPS-R threshold (≤ 20 vs. \> 20, indicating ED risk).

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • De Paoli T, Rogers PJ. Disordered eating and insulin restriction in type 1 diabetes: A systematic review and testable model. Eat Disord. 2018 Jul-Aug;26(4):343-360. doi: 10.1080/10640266.2017.1405651. Epub 2017 Nov 28. PubMed 29182474 ↗
  • Palmieri S, Mansueto G, Ruggiero GM, Caselli G, Sassaroli S, Spada MM. Metacognitive beliefs across eating disorders and eating behaviours: A systematic review. Clin Psychol Psychother. 2021 Sep;28(5):1254-1265. doi: 10.1002/cpp.2573. Epub 2021 Feb 23. PubMed 33606916 ↗
  • Cheng R, Taleb N, Stainforth-Dubois M, Rabasa-Lhoret R. The promising future of insulin therapy in diabetes mellitus. Am J Physiol Endocrinol Metab. 2021 May 1;320(5):E886-E890. doi: 10.1152/ajpendo.00608.2020. Epub 2021 Mar 15. PubMed 33719586 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2025, 8 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 8 months is below that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Jun 15, 2025
StartActual
Apr 14, 2025
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07021456
Collaborators
Laboratoire TIMC-IMAG
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Apr 14, 2025
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jun 15, 2025

Study contacts

Cécile BERTY
Contact
CBetry@chu-grenoble.fr
0476765509
Laura ALBALADEJO
Contact
LAlbaladejo@chu-grenoble.fr
0476765509

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion